For any further information
Our story
Resono Ophthalmic is the result of the long and fascinating journey of the founders intertwining science, technology, and entrepreneurship. The company is established in 2014 as an Innovative Startup and, in 2019, it becomes an innovative SME.
Its mission is the development and marketing of highly innovative therapeutic devices for ophthalmology.
The journey
Resono Ophthalmic originates from Alfredo Ruggeri’s intuition to apply to ophthalmology the Quantum Molecular Resonance (QMR) principle, a technology capable of stimulating natural cell and tissue regeneration through high frequency and low power electric fields, already applied for years in various medical fields.
Ophthalmology was one of Alfredo’s main areas of study and research during his career as a Professor of Biomedical Instrumentation at the University of Padua. During those years, he comes into contact and actively collaborates with various companies that develop medical devices, including Nidek Technologies, belonging to the Japanese group Nidek Co., a world leader in ophthalmic instrumentation, and Telea Medical, which had developed an innovative technology, capable of stimulating natural cell regeneration, called Quantum Molecular Resonance (QMR). He also participates as co-founder in the creation of the business incubator M31, within which successful companies in the ophthalmology field such as CenterVue, Adaptica and D-Eye are established.
Resono Ophthalmic is born
It is precisely from this stimulating intertwining of skills and knowledge that the entrepreneurial idea of applying QMR technology to the treatment of eye diseases originates.
The Telea Medical company, experts in Business Development and Sales & Marketing, and a local backer, support him in establishing the business.
After several interviews with ophthalmologists and researchers, interest initially turns to dry eye disease, the most widespread in the ophthalmology field, and leads to the development of the innovative Rexon-Eye device, the first product of the new company.
Founders
Alfredo Ruggeri
More Info
Former Associate Professor of Biomedical Engineering, University of Padua.
Founding partner, M31 (technology incubator – CenterVue, Adaptica, D-Eye).
Research and development consultant for several ophthalmology companies (Nidek Technologies, CenterVue, Cooper Vision).
Pietro Torrusio
More Info
Degree in Political Sciences from University of Milan.
General Manager, Althea Group (European leader in Healthcare Technology Management).
Former CEO, GE Medical Systems Iberia.
Former Chairman and CEO, Kontron Instruments.
Telea Medical Group
More Info
Biomedical Equipment Company.
QMR technology developer.
MS Growth Ventures
More Info
Venture Capital & Private Equity Company (London and Milan).
Bertuzzo Srl
More Info
Financial investor.
Board of Directors
Alfredo Ruggeri
Chairman and CEO
More Info
Former Associate Professor of Biomedical Engineering, University of Padua.
Founding partner, M31 (technology incubator – CenterVue, Adaptica, D-Eye).
Research and development consultant for several ophthalmology companies (Nidek Technologies, CenterVue, Cooper Vision).
Carlo Solcia
Member
More Info
Founder and CEO MS Growth Ventures, Italy/UK (technology early-stage investment).
Executive Director Lipogems International Italy/USA (regenerative medical-biotech).
Formerly in Bain & Company (management consulting).
Giuliano Barbaro
Member
More Info
Co-founder and Executive Director CenterVue (now Revenio), Italy/Finland (ophthalmic devices).
Former R&D Manager and General Manager Nidek Technologies, Italy/Japan (ophthalmic devices).
Alessandro Pozzato
Member
More Info
Degree in Electronics Engineering from University of Padua.
R&D Manager, Telea Medical, Medical Device company.
Co-developer of QMR technology.
Vincenzo Cipullo
Member
More Info
Degree in Electrical Engineering from University of Genoa.
Former General Manager at Metalgraf Iberia and Eurobox.